Who
Richard Brudnick
Director
Company insider
Files Form 4 as: Director, Scholar Rock Holding; Chief Business Officer, Prime Medicine; Director, VolitionRX; Officer, Codiak BioSciences; EVP, Business Development, Bioverativ.
In numbers
- Trades disclosed
- 61
- Buys
- 1
- Sells
- 1
- Bought
- $24K
- Sold
- $181K
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 14 Feb 2017
- Last trade
- 4 Jun 2026
- Last filed
- 8 Jun 2026
Companies traded
Activity over time
1 May 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Jun 2026filed 8 Jun 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code A | —6,839 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | SRRK Scholar Rock Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,310 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | SRRK Scholar Rock Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,310 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code A | —6,839 at $0.00 | filing |
| 29 May 2025filed 30 May 2025 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $139K4,675 at $29.63 | filing |
| 29 May 2025filed 30 May 2025 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $42K1,400 at $30.00 | filing |
| 22 May 2025filed 23 May 2025 | SRRK Scholar Rock Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,206 at $0.00 | filing |
| 22 May 2025filed 23 May 2025 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code A | —7,632 at $0.00 | filing |
| 20 May 2025filed 22 May 2025 | PRME Prime MedicineBiotechnology | SEC FORM 4 Bought | $24K20,000 at $1.19 | filing |
| 27 Feb 2025filed 3 Mar 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —225,000 at $0.00 | filing |
| 5 Dec 2024filed 9 Dec 2024 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,300 at $0.00 | filing |
| 27 Jun 2024filed 1 Jul 2024 | SRRK Scholar Rock Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 27 Jun 2024filed 1 Jul 2024 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code A | —13,500 at $0.00 | filing |
| 17 May 2024filed 21 May 2024 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,300 at $0.00 | filing |
| 21 Feb 2024filed 23 Feb 2024 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —135,747 at $0.00 | filing |
| 6 Apr 2023filed 10 Apr 2023 | SRRK Scholar Rock Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —56,000 at $0.00 | filing |
| 31 Mar 2023filed 4 Apr 2023 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —135,747 at $0.00 | filing |
| 12 Jan 2023filed 13 Jan 2023 | VNRX VolitionRXDiagnostics & Labs | SEC FORM 4 Code A | —5,625 at $0.00 | filing |
| 13 Oct 2022filed 14 Oct 2022 | VNRX VolitionRXDiagnostics & Labs | SEC FORM 4 Code A | —2,625 at $0.00 | filing |
| 23 Jun 2022filed 24 Jun 2022 | VNRX VolitionRXoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —5,613 at $0.00 | filing |
News
Scholar Rock Resubmits Marketing Authorisation Application For ApitegromabSRRK · rttnews.com · 8 Oct 2026
0 headlines in the last 90 days name Richard Brudnick; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.